265: Novavax's CEO promises a turnaround & how Lilly roiled the obesity market
The Readout Loud
00:00
The Risks of Failure
"There's significant execution risk to this business between now and the end of the year," he said. "I know we have the right plan. And so far we've executed exquisitely well against that plan" He added: "We are not looking for a short-term bump in the stock price at all."
Play episode from 28:43
Transcript
